Yes, very sweet!!lucyinthesky Share Thursday, January 19, 2012 3:15:48 PM
Re: None Post # of 93157

Dow Jones Chart, very BULLISH.

Nice news$$!!Medical Alarm Announces Media Schedule for MediPendant™ Nationwide Television Launch

2012-01-19 09:00 ET - News Release




KING OF PRUSSIA, Pa., Jan. 19, 2012 /PRNewswire/ -- Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK), manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows the user to speak and listen directly through the pendant, today announced that the initial scheduling of its television advertising campaign for the MediPendant™ personal medical alarm will kick off on Friday, January 27, 2012 on several national cable network stations.

"We have designed a very robust campaign to target the multi-million dollar personal medical alarm segment. We strongly believe we have a significant technology advantage with our fully monitored two-way through the pendant voice technology. A tremendous amount of work has gone into designing this new campaign," commented Jennifer Loria, VP of Corporate Development at Medical Alarm Concepts. "We now have a specialty call center onboard that is extremely experienced in the personal medical alarm market. They will be able to offer subscribers quick turnaround and 24 hour customer service. We have also developed a unique financing arrangement that will allow us to recoup all of our costs plus realize profit upon the initial sale, instead of having to wait for the monthly annuity stream that is the norm in this marketplace. Additionally our partners, Harrington Multimedia, are one of the most successful companies within the television and Internet direct marketing channels."

Howard Teicher, CEO of Medical Alarm Concepts added, "We have been extremely busy over the past few months, and are confident that we will continue putting together the programs needed to move this company forward during 2012. The Company is now well-positioned with a premier marketing partner to help us move our specialized patented product."

About Medical Alarm Concepts

Medical Alarm Concepts Holding, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. We have built our reputation in the personal emergency response system (PERS) and medical alert industry. With patented technology and state-of-the-art services, MAC is uniquely positioned to mobilize the right people, skills and alliances to ensure success and client satisfaction. Our design and support philosophy emphasizes industry best practices, while providing polished and savvy solutions. MAC's latest innovation is the development of its two-way voice speakerphone pendant technology. For more information, please visit our website at www.medipendant.com.

Safe Harbor Statement

Statements in this press release that are

BISU 2-3 months againand BOOOM!

action start in february for BISU!!

MDHI radar!for bottom play.. We are optimistic that the commercial makes a compelling offer and will drive sales," said Paul Green..!!

HMMM!!!...metza45 Share Wednesday, January 18, 2012 6:30:34 PM
Re: cjstocksup post# 4990 Post # of 5030

CJ - the 7 million dollar deficit was reported by MDHI in their financials.
Any company that touts having the "best product on the market" doesn't have 7 million dollar deficits.

They don't have 0 CASH.

They don't warn their shareholders of possibly having to cease the operation and close the doors.

quote]LMAO! This is such good reading for humor. There is not a single big board stock that does not have similar disclosures on ALLof their filings. I used to handle investments for as living back in the 80's. I bet I retired before most here were even born. The charts do not lie. I am going to love seeing some shorts and naked shorts get crushed big time going forwrd. MDHI
--------------------------------------------------------------------------------


Medical Alarm Concepts and Harrington Multi Media Ready for MediPendant™ National Television Campaign Test Launch

2012-01-12 09:00 ET - News Release




KING OF PRUSSIA, Pa., Jan. 12, 2012 /PRNewswire/ -- Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK), manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows the user to speak and listen directly through the pendant, today announced that post-production of the new MediPendant™ television commercial is complete and a national test launch will begin as early as the last week of January.

Harrington Multi Media Marketing has completed post-production of the two-minute commercial promoting the MediPendant Plus, a MediPendant™ medical alarm device with additional services included in its service package. "We are very excited to test the new commercial produced by Harrington. It really drives home the competitive advantages that MediPendant Plus has over its competitors. We are optimistic that the commercial makes a compelling offer and will drive sales," said Paul Green, VP of Sales and Marketing at Medical Alarm Concepts. We had a lot of success with our first commercial, and now with Harrington on board, we feel confident that this commercial will be even more successful, adds Green.

The completed commercial will be sent to the stations participating in the test, by media agency Modus Direct. Tim Harrington, CEO of Harrington Multi Media stated, "The selection of the right media agency to buy media for a commercial is important to a successful media test. We believe that Modus Direct is the right agency for the MediPendant Plus. Over the years they have managed campaigns for Hoveround, WoundSeal (this includes a drive to a retail program for Walgreens), 911 Medical ID, Indulge-a-Bath, Leading Medical Incontinence, and Uplift Technologies Chairlifts."

Mike Altieri, who is overseeing the media campaign for MediPendant Plus at Modus Direct added, "We feel very confident that we can get the MediPendant Plus commercial in front of the right audience. At present, Modus is probably the most versed company in the senior category in terms of media learning and relevant current station data."



Under the terms of the signed agreement, Harrington will finance and produce multiple television spots and an Internet-based marketing campaign for the MediPendant™. Harrington will be responsible for all of its costs in connection with the marketing of the products. This will include financing all television media and purchasing units from the Company at a pre-arranged price. Medical Alarm Concepts will book all revenue from the joint venture. About Medical Alarm Concepts

Medical Alarm Concepts Holding, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. We have built our reputation in the personal emergency response system (PERS) and medical alert industry. With patented technology and state-of-the-art services, MAC is uniquely positioned to mobilize the right people, skills and alliances to ensure success and client satisfaction. Our design and support philosophy emphasizes industry best practices, while providing polished and savvy solutions. MAC's latest innovation is the development of its two-way voice speakerphone pendant technology. For more information, please visit our website at www.medipendant.com.


About Harrington Multi Media Marketing LLC

Harrington Multi Media Marketing LLC (HM3) is a leading producer of infomercials and short-form direct television spots and developer of Internet-based marketing campaigns and transactional websites. HM3 also offers complete turnkey solutions to launch new consumer products including: complete production services on a for-hire basis, assistance with outsourcing products and prototype development; set-up and management of call centers; product fulfillment and customer service; credit card processing; purchasing and management of media outlets, including telephone sales, direct response television (DRTV), and Internet sales. Tim Harrington, CEO of HM3, is one of the pioneers of the direct response marketing industry and has been in the business over 25 years. Over the course of 25 years in this industry Tim Harrington's companies have generated over 4 billion dollars in sales of products and services. HM3 is a member of the Electronics Retailing Association which is the governing body for this industry, and which association was co-founded by one of Tim Harrington's previous companies. For more information, please visit www.hm3.com.


Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.

Contact:
Medical Alarm Concepts Holding, Inc.
1-877-639-2929 Ext. 113

SOURCE Medical Alarm Concepts Holding, Inc.

bala TLPH Nice PRrrrrtoday<<Teliphone Corp. Reports 2011 Year-End Results2012-01-18 12:20 ET - News Release


Adjusted net earnings rose to $501k, up from a loss of $192k in 2010
Adjusted net income increased to $2 million or $0.05 per share, up from a loss of $590k or ($0.02) per share in 2010
Total shareholder equity rose to $2.4 million or $0.06 per share (including a stock issuance of $470k) up from a deficit of $460k or $0.01 per share
TORONTO, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Teliphone Corp. (OTCQB:TLPH) the world's local digital telecommunications company announced the results for its year end September 30, 2011. This is the first report of annual earnings after the April 1, 2011 disposition of its majority-owned subsidiary, Teliphone Inc. therefore results are not directly comparable to prior periods.

Consolidated results net revenue for the year ending September 30, 2011 was $2,257,385 a 20-fold increase from year end September 30 2010. These revenues represent six months of operations after the disposition of Teliphone Inc. Accounting for discontinued operations from its former subsidiary Teliphone Inc., revenues were $4,694,393, up 0.7% from $4,663,201 in 2010. Consolidated net income from operations was $501,269 in 2011 up from a loss of $192,952 in 2010. Teliphone Corp. also recorded a one time net gain of $1,514,629 from the disposition of Teliphone Inc. and will retain ongoing revenues from the former subsidiary. The adjusted net income was $2,015,898 in 2011, up from a loss of $590,041 in 2010. Earnings per share in 2011 were $0.05 ($0.01 from operations and $0.04 from the disposition of Teliphone Inc.), up from a loss of $0.02 and the accumulated deficit was $224,852, down from $2,240,750 in 2010. Total shareholder equity in 2011 rose to $1,926,756 or $0.05 per share from a deficit of $435,694 or ($0.01 per share) in 2010. The 2011 figure includes $469,868 liability for shares to be issued. These shares were issued in September 2011 and adjusting for this, the shareholder equity was $2,396,624 or $0.06 per share.

Lawry Trevor-Deutsch, President and CEO stated, "In 2011 we worked hard to accomplish major restructuring of the company which has resulted in significant improvements to our balance sheet and net income and putting us in an excellent position for growth in 2012. In 2012 we intend to focus on both increased sales of our traditional offerings as well as the launch of an expanded line of services for both business and consumers. We also intend to reduce our cost base by shortening our supply chain and re-negotiating supply agreements. Along with the acquisition of the New York Telecom Exchange (NYTEX) in December 2011 and the expansion of our telecommunications infrastructure, Teliphone Corp. is now poised for growth in all three major areas of telecommunications; wholesale, commercial and retail."

About Teliphone

Teliphone Corp. is the world's local digital telecommunications company providing Internet, voice, IPTV, digital content and data services to business, government and residential customers. Teliphone operates a Canadian coast to coast network with its own national infrastructure and its voice and IPTV services are also available in 47 countries. Teliphone is able to deliver more value added services to its customers at a lower cost than other suppliers.

NYTEX is an international telecommunications commodity exchange which uses a proprietary algorithm which commoditizes international telecommunications minutes. NYTEX also developed the concept of trading of blocks of minutes and when used in conjunction with the algorithm allows minutes to be traded like any other commodity as in other mercantile exchanges. NYTEX provides a trading platform for wholesale carriers, mobile and fixed network operators and retail operators and acts as the central clearing house to all exchange-traded transactions therefore ensuring the delivery and fulfillment of these transactions. NYTEX has data centers in Montreal (NYTEX), London (LondonTelex) and Brussels (Europe Telecom Exchange).

Forward-Looking Statements

This press release includes "forward-looking statements" as defined by the SEC. All statements, other than statements of historical fact, included herein that address activities, events or developments that Teliphone Corp. or New York Telecom Exchange Inc. expects, believes or anticipates will or may occur in the future, including anticipated benefits and other aspects of the proposed acquisition, are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of their dates. Except as required by law, neither Teliphone Corp. nor the New York Telecom Exchange Inc. intends to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Lawry Trevor-Deutsch
President, Teliphone Corp.
Tel: +1 514 313 6000
info@teliphone.ca

MDHI ok thx on watch!

hey muga$radar WTCT>don't forget NEPT>>revenue..to>>$5,120,000 Neptune Reports Third Quarter Results

2012-01-17 08:00 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial results for the three-month and nine-month periods ended November 30, 2011.

Three-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 20% to $5,120,000, for the three-month period ended November 30, 2011, up from $4,272,000 achieved during the corresponding period ended November 30, 2010.
Nutraceutical EBITDA increased to $1,081,000, for the three-month period ended November 30, 2011, up from $425,000 achieved during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $869,000 for the three-month period ended November 30, 2011, compared to a net loss of $13,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 19% to $5,124,000 for the three-month period ended November 30, 2011, up from $4,290,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the three-month period ended November 30, 2011 amounted to ($743,000), compared to ($156,000) obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $1,433,000 for the three-month period ended November 30, 2011, compared to a net loss of $498,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding performance from the neutraceutical business of Neptune," said Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to our leadership positions in North America and Europe, where we have grown both sales and market share this year. We look forward to this afternoon conference call, as we will give a full corporate update to our shareholders," he added.

"We continue to build momentum as demonstrated by our solid third quarter results. During the third quarter our long-term strategic investments in the company's intellectual property protection and valorization helped drive strong revenue performance," said Frederic Harland, Director of finance. "As we look back at the past quarters, we expect continued sales growth driven by price and quantities and are confident in our growth strategy and commercial plans," he added.

Nine-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 10% to $13,756,000, for the nine-month period ended November 30, 2011, up from $12,504,000 achieved during the corresponding period ended November 30, 2010.
EBITDA from nutraceutical business for the nine-month period ended November 30, 2011 was $2,505,000, compared to $2,787,000 obtained during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $1,005,000 for the nine-month period ended November 30, 2011, compared to a net income of $1,996,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 10% to $13,770,000 for the nine-month period ended November 30, 2011, up from $12,566,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the nine-month period ended November 30, 2011 amounted to a negative $1,818,000, compared to $1,345,000 obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $4,459,000 for the nine-month period ended November 30, 2011, compared to a net income of $519,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements» within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com

178!!!.have fun$$$$Take your ticket$

SNGX nice PR today

thx, 300% up in one week..and Huge PR coming!!

bala Nice$$ profit today thx.

sweet))) Current status - Buyback(0.025) - new IPO Graffiti Entertainment - coming soon!! $

2012-01-17 09:18 SDVI News Release SDVI's New Reader Rabbit App Ranks Highly on Sales Charts for iPad(R), iPhone(R) and iPod(R); Reader Rabbit Is a Hit for the iPad(R) Generation of Youngsters
2012-01-11 13:05 SDVI News Release Signature Devices, Inc. Offers New Reader Rabbit Apps for Kids on Apple(R) iTunes(R) With Three Titles Available Today
2011-12-27 14:45 SDVI News Release Signature Devices, Inc. to Release Four New Apple Apps in 2012 First Quarter

Q1 will be HUGE..
Reader Rabbit Kindergarten - 489344055 (last update 18th Jan 2012)
Reader Rabbit Preschool - 473567305 (last update 18th Jan 2012)
Reader Rabbit 1st Grade - 492174603 (last update 18th Jan 2012)
Reader Rabbit 2nd Grade - 489350280 (last update 18th Jan 2012)

Country Games/Educational Games/Adventure
Australia 20 [60] 67 [178]
Canada 45 [75] 95 [191]
Czech Republic 82 [74]
United States 86 [106] 190 [0]
Philippines 97 [85]
New Zealand 110 [96]
Sweden 135 [125]
Japan 154 [131]

http://www.applyzer.com/main.php



SDVI's New Reader Rabbit App Ranks Highly on Sales Charts for iPad(R), iPhone(R) and iPod(R); Reader Rabbit Is a Hit for the iPad(R) Generation of Youngsters

2012-01-17 09:18 ET - News Release

REDWOOD CITY, CA -- (MARKET WIRE) -- 01/17/12

Reader Rabbit has been teaching and educating children for 25 years and now he is a leader in iPad® and iPhone®/iPod® Touch games for a new generation of young people, thanks to newly released games from Signature Devices Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment.
On Monday, January 16, APPlyzer, an independent service ranking the top 1000 apps, reported the following top sales positions for Reader Rabbit 1st Grade. Of millions of apps on the market, these are the current standings.
iPad® Rankings for Games/Educational, Reader Rabbit 1st Grade ranks:
United States, #125; Canada, #146; Japan, #196; New Zealand, #83; Philippines, #77; Czech Republic #71, and Australia #66.
iPhone®/iPod® Rankings for Games/Educational, Reader Rabbit 1st Grade ranks:
United States #500, United Kingdom #715, Australia #340, Canada #261, and New Zealand, #181.
"We are so excited to bring Reader Rabbit to iTunes, and especially to be scoring a top marketing hit for the Apple iPad tablets, which truly offer the kind of interactive features that Signature Devices Inc. and our subsidiary Graffiti Entertainment excel at creating and marketing," said Mart van der Velde, CEO, SDVI.
"With this initial 2012 sales success, the stage is set for increased viral marketing to reach a potential breakthrough my plans as CEO to help lead a global expansion of our company with increased sales, increased awareness and brining more high quality products to the market," Mr. van der Velde added.
The Reader Rabbit apps now available in iTunes are Reader Rabbit Preschool, Reader Rabbit Kindergarten and Reader Rabbit 1st Grade. With interactive fun, they teach math, science, problem-solving, art and language arts skills.
The Reader Rabbit series has sold over 25 MILLION COPIES since 1993 and has won over 175 AWARDS and accolades! Every product under the Reader Rabbit brand undergoes extensive research and testing, with input from parents, children, and professionals in education. Each product features a precise balance of educational content and entertainment value, so children have fun while learning.
About Signature Devices, Inc.:


Signature Devices, Inc. Offers New Reader Rabbit Apps for Kids on Apple(R) iTunes(R) With Three Titles Available Today

2012-01-11 13:05 ET - News Release

REDWOOD CITY, CA -- (MARKET WIRE) -- 01/11/12

Signature Devices, Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment, proudly announce the immediate availability in the Apple® iTunes® store of three amazing and fun educational apps for children. Reader Rabbit Preschool, Reader Rabbit Kindergarten, and Reader Rabbit First Grade were all developed in-house. They are fully interactive.
"Our creative team has delivered a suite of children's apps that can have a huge appeal and audience. Based on the long-running and popular Reader Rabbit series, we have packed these apps with creativity and technology to assure the largest possible commercial audience. They are priced at $2.99 each, putting them in the reach of all parents and grandparents," said Mart van der Velde, CEO.
"This is the right product to kick off 2012 with a fresh start for Signature Devices, Inc. A success in the children's app market can put a company like ours in a great position for growth, and with these Reader Rabbit apps, we have delivered the goods to the biggest growing segment of the children's educational marketplace. We see large revenue potential in these titles," he added.
Reader Rabbit from SDVI's Graffiti Entertainment is an educational adventure game based on the characters of the popular series for young children, Reader Rabbit. The games teach basic skills to prepare kids for success at school and provide a foundation for further learning.
The games are presented in a colorful cartoon style with short videos, full voice acting, and sing-along songs designed to engage young children while still teaching basic skills. Players will be able to adjust the difficulty level of all mini-games independently which can add hours of replay value.
Great story lines engage children in the interactive fun. In Reader Rabbit First Grade, children help Reader Rabbit and Sam the Lion explore Cloud Nine and Raingear Island in search of the things that Irvin needs. If they find the three items and bring them back to Irvin, he will turn off his machine and stop the avalanche of raingear.
About Signature Devices, Inc.:
Based in Redwood City, Calif., Signature Devices, Inc. (SDVI) creates, develops and manufactures advanced information technology, including computer systems, software and electronics products. One of the Company's premier technologies includes a blend of hardware and software for image generation technology used in video games and simulations. Signature Devices also owns Graffiti Entertainment, Inc. (www.graffitientertainment.com), a publisher of interactive entertainment software for advanced entertainment conso

Good luck with your Ja_l..let$$ rok !!!!!!!!!02/01/2012 09:32:44 AM

Bull

Close is ok here!!

Nice action very soon bud!!$

SDVI CURRENT STATUS$$$$..cominggg!!

SDVI UP!!!42% nice pr

09:40:34 Q 0.0009 0.0002 1,210,000
09:40:14 Q 0.0009 0.0002 26,700
09:40:08 Q 0.0009 0.0002 100,000

09:37:30 Q 0.0008 0.0001 338,000
09:37:04 Q 0.0008 0.0001 100,000
09:36:55 Q 0.0008 0.0001 690,000
09:36:17 Q 0.0008 0.0001 25,000
09:34:40 Q 0.0008 0.0001 115,000
09:34:21 Q 0.0008 0.0001 5,000
09:33:26 Q 0.0008 0.0001 5,000
09:33:21 Q 0.0008 0.0001 120,000
09:32:11 Q 0.0007 80,048
09:31:51 Q 0.0007 3,000

SDVI>>>SDVI's New Reader Rabbit App Ranks Highly on Sales Charts for iPad(R), iPhone(R) and iPod(R); Reader Rabbit Is a Hit for the iPad(R) Generation of Youngsters

2012-01-17 09:18 ET - News Release


REDWOOD CITY, CA -- (MARKET WIRE) -- 01/17/12


Reader Rabbit has been teaching and educating children for 25 years and now he is a leader in iPad® and iPhone®/iPod® Touch games for a new generation of young people, thanks to newly released games from Signature Devices Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment.

On Monday, January 16, APPlyzer, an independent service ranking the top 1000 apps, reported the following top sales positions for Reader Rabbit 1st Grade. Of millions of apps on the market, these are the current standings.
iPad® Rankings for Games/Educational, Reader Rabbit 1st Grade ranks:

United States, #125; Canada, #146; Japan, #196; New Zealand, #83; Philippines, #77; Czech Republic #71, and Australia #66.

iPhone®/iPod® Rankings for Games/Educational, Reader Rabbit 1st Grade ranks:

United States #500, United Kingdom #715, Australia #340, Canada #261, and New Zealand, #181.

"We are so excited to bring Reader Rabbit to iTunes, and especially to be scoring a top marketing hit for the Apple iPad tablets, which truly offer the kind of interactive features that Signature Devices Inc. and our subsidiary Graffiti Entertainment excel at creating and marketing," said Mart van der Velde, CEO, SDVI.

"With this initial 2012 sales success, the stage is set for increased viral marketing to reach a potential breakthrough my plans as CEO to help lead a global expansion of our company with increased sales, increased awareness and brining more high quality products to the market," Mr. van der Velde added.

The Reader Rabbit apps now available in iTunes are Reader Rabbit Preschool, Reader Rabbit Kindergarten and Reader Rabbit 1st Grade. With interactive fun, they teach math, science, problem-solving, art and language arts skills.

The Reader Rabbit series has sold over 25 MILLION COPIES since 1993 and has won over 175 AWARDS and accolades! Every product under the Reader Rabbit brand undergoes extensive research and testing, with input from parents, children, and professionals in education. Each product features a precise balance of educational content and entertainment value, so children have fun while learning.

About Signature Devices, Inc.:
Based in Redwood City, Calif., Signature Devices, Inc. (SDVI) creates, develops and manufactures advanced information technology, including computer systems, software and electronics products. One of the Company's premier technologies includes a blend of hardware and software for image generation technology used in video games and simulations. Signature Graffiti Entertainment, Inc. (www.graffitientertainment.com) is a publisher of interactive entertainment software for advanced entertainment consoles.

The information in this press release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct

$$have a great day$$

NEPT revenue increased by 20% to $5,120,000 Neptune Reports Third Quarter Results

2012-01-17 08:00 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial results for the three-month and nine-month periods ended November 30, 2011.

Three-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 20% to $5,120,000, for the three-month period ended November 30, 2011, up from $4,272,000 achieved during the corresponding period ended November 30, 2010.
Nutraceutical EBITDA increased to $1,081,000, for the three-month period ended November 30, 2011, up from $425,000 achieved during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $869,000 for the three-month period ended November 30, 2011, compared to a net loss of $13,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 19% to $5,124,000 for the three-month period ended November 30, 2011, up from $4,290,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the three-month period ended November 30, 2011 amounted to ($743,000), compared to ($156,000) obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $1,433,000 for the three-month period ended November 30, 2011, compared to a net loss of $498,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding performance from the neutraceutical business of Neptune," said Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to our leadership positions in North America and Europe, where we have grown both sales and market share this year. We look forward to this afternoon conference call, as we will give a full corporate update to our shareholders," he added.

"We continue to build momentum as demonstrated by our solid third quarter results. During the third quarter our long-term strategic investments in the company's intellectual property protection and valorization helped drive strong revenue performance," said Frederic Harland, Director of finance. "As we look back at the past quarters, we expect continued sales growth driven by price and quantities and are confident in our growth strategy and commercial plans," he added.

Nine-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 10% to $13,756,000, for the nine-month period ended November 30, 2011, up from $12,504,000 achieved during the corresponding period ended November 30, 2010.
EBITDA from nutraceutical business for the nine-month period ended November 30, 2011 was $2,505,000, compared to $2,787,000 obtained during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $1,005,000 for the nine-month period ended November 30, 2011, compared to a net income of $1,996,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 10% to $13,770,000 for the nine-month period ended November 30, 2011, up from $12,566,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the nine-month period ended November 30, 2011 amounted to a negative $1,818,000, compared to $1,345,000 obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $4,459,000 for the nine-month period ended November 30, 2011, compared to a net income of $519,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements» within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights




Acasti Pharma Reports Third Quarter Results

2012-01-17 08:01 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti") (TSX.V:APO), a Neptune Technologies & Bioressources Inc's ("Neptune") subsidiary, today report its financial results for the three and nine-month periods ended November 30, 2011.

Three-Month period

Research and development expenses for the three-month period ended November 30, 2011 amounted to $1,371,000 compared to $354,000 for the corresponding period ended November 30, 2010.
EBITDA for the three-month period ended November 30, 2011 resulted in a negative $1,677,000, compared to a negative $567,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $2,207,000, or $0.03 per share for the three-month period ended November 30, 2011, compared to $618,000, or $0.02 per share, for the corresponding period ended November 30, 2010.
Nine-Month period

Research and development expenses for the nine-month period ended November 30, 2011 amounted to $2,745,000 compared to $942,000 for the corresponding period ended November 30, 2010.
EBITDA for the nine-month period ended November 30, 2011 resulted in a negative $3,624,000, compared to a negative $1,373,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $4,954,000, or $0.08 per share for the nine-month period ended November 30, 2011, compared to $1,866,000, or $0.14 per share, for the corresponding period ended November 30, 2010.
About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Suchforward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could causethe actual results of the Company to be materially different from historical results or from any future results expressed orimplied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with theSecurities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
Tina Sampalis
President
+1 450.686.4555
t.sampalis@acastipharma.com

Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
www.acastipharma.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights reserved. "Stockwatch" is a registered trademark of Canjex Publishing Ltd. Terms of Use, Privacy Policy

Gm bala,great result$>>NEPT<<revenue..increased to $5,120,000
Neptune Reports Third Quarter Results

2012-01-17 08:00 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial results for the three-month and nine-month periods ended November 30, 2011.

Three-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 20% to $5,120,000, for the three-month period ended November 30, 2011, up from $4,272,000 achieved during the corresponding period ended November 30, 2010.
Nutraceutical EBITDA increased to $1,081,000, for the three-month period ended November 30, 2011, up from $425,000 achieved during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $869,000 for the three-month period ended November 30, 2011, compared to a net loss of $13,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 19% to $5,124,000 for the three-month period ended November 30, 2011, up from $4,290,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the three-month period ended November 30, 2011 amounted to ($743,000), compared to ($156,000) obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $1,433,000 for the three-month period ended November 30, 2011, compared to a net loss of $498,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding performance from the neutraceutical business of Neptune," said Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to our leadership positions in North America and Europe, where we have grown both sales and market share this year. We look forward to this afternoon conference call, as we will give a full corporate update to our shareholders," he added.

"We continue to build momentum as demonstrated by our solid third quarter results. During the third quarter our long-term strategic investments in the company's intellectual property protection and valorization helped drive strong revenue performance," said Frederic Harland, Director of finance. "As we look back at the past quarters, we expect continued sales growth driven by price and quantities and are confident in our growth strategy and commercial plans," he added.

Nine-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 10% to $13,756,000, for the nine-month period ended November 30, 2011, up from $12,504,000 achieved during the corresponding period ended November 30, 2010.
EBITDA from nutraceutical business for the nine-month period ended November 30, 2011 was $2,505,000, compared to $2,787,000 obtained during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $1,005,000 for the nine-month period ended November 30, 2011, compared to a net income of $1,996,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 10% to $13,770,000 for the nine-month period ended November 30, 2011, up from $12,566,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the nine-month period ended November 30, 2011 amounted to a negative $1,818,000, compared to $1,345,000 obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $4,459,000 for the nine-month period ended November 30, 2011, compared to a net income of $519,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements» within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights




Acasti Pharma Reports Third Quarter Results

2012-01-17 08:01 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti") (TSX.V:APO), a Neptune Technologies & Bioressources Inc's ("Neptune") subsidiary, today report its financial results for the three and nine-month periods ended November 30, 2011.

Three-Month period

Research and development expenses for the three-month period ended November 30, 2011 amounted to $1,371,000 compared to $354,000 for the corresponding period ended November 30, 2010.
EBITDA for the three-month period ended November 30, 2011 resulted in a negative $1,677,000, compared to a negative $567,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $2,207,000, or $0.03 per share for the three-month period ended November 30, 2011, compared to $618,000, or $0.02 per share, for the corresponding period ended November 30, 2010.
Nine-Month period

Research and development expenses for the nine-month period ended November 30, 2011 amounted to $2,745,000 compared to $942,000 for the corresponding period ended November 30, 2010.
EBITDA for the nine-month period ended November 30, 2011 resulted in a negative $3,624,000, compared to a negative $1,373,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $4,954,000, or $0.08 per share for the nine-month period ended November 30, 2011, compared to $1,866,000, or $0.14 per share, for the corresponding period ended November 30, 2010.
About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Suchforward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could causethe actual results of the Company to be materially different from historical results or from any future results expressed orimplied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with theSecurities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
Tina Sampalis
President
+1 450.686.4555
t.sampalis@acastipharma.com

Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
www.acastipharma.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights reserved. "Stockwatch" is a registered trademark of Canjex Publishing Ltd. Terms of Use, Privacy Policy

CERP nice call Mr shake

Acasti Pharma Reports Third Quarter Results
2012-01-17 08:01 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti") (TSX.V:APO), a Neptune Technologies & Bioressources Inc's ("Neptune") subsidiary, today report its financial results for the three and nine-month periods ended November 30, 2011.

Three-Month period

Research and development expenses for the three-month period ended November 30, 2011 amounted to $1,371,000 compared to $354,000 for the corresponding period ended November 30, 2010.
EBITDA for the three-month period ended November 30, 2011 resulted in a negative $1,677,000, compared to a negative $567,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $2,207,000, or $0.03 per share for the three-month period ended November 30, 2011, compared to $618,000, or $0.02 per share, for the corresponding period ended November 30, 2010.
Nine-Month period

Research and development expenses for the nine-month period ended November 30, 2011 amounted to $2,745,000 compared to $942,000 for the corresponding period ended November 30, 2010.
EBITDA for the nine-month period ended November 30, 2011 resulted in a negative $3,624,000, compared to a negative $1,373,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $4,954,000, or $0.08 per share for the nine-month period ended November 30, 2011, compared to $1,866,000, or $0.14 per share, for the corresponding period ended November 30, 2010.
About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Suchforward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could causethe actual results of the Company to be materially different from historical results or from any future results expressed orimplied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with theSecurities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
Tina Sampalis
President
+1 450.686.4555
t.sampalis@acastipharma.com

Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
www.acastipharma.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com

Neptune Reports Third Quarter Results>>>>>NEPT
2012-01-17 08:00 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial results for the three-month and nine-month periods ended November 30, 2011.

Three-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 20% to $5,120,000, for the three-month period ended November 30, 2011, up from $4,272,000 achieved during the corresponding period ended November 30, 2010.
Nutraceutical EBITDA increased to $1,081,000, for the three-month period ended November 30, 2011, up from $425,000 achieved during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $869,000 for the three-month period ended November 30, 2011, compared to a net loss of $13,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 19% to $5,124,000 for the three-month period ended November 30, 2011, up from $4,290,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the three-month period ended November 30, 2011 amounted to ($743,000), compared to ($156,000) obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $1,433,000 for the three-month period ended November 30, 2011, compared to a net loss of $498,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding performance from the neutraceutical business of Neptune," said Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to our leadership positions in North America and Europe, where we have grown both sales and market share this year. We look forward to this afternoon conference call, as we will give a full corporate update to our shareholders," he added.

"We continue to build momentum as demonstrated by our solid third quarter results. During the third quarter our long-term strategic investments in the company's intellectual property protection and valorization helped drive strong revenue performance," said Frederic Harland, Director of finance. "As we look back at the past quarters, we expect continued sales growth driven by price and quantities and are confident in our growth strategy and commercial plans," he added.

Nine-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 10% to $13,756,000, for the nine-month period ended November 30, 2011, up from $12,504,000 achieved during the corresponding period ended November 30, 2010.
EBITDA from nutraceutical business for the nine-month period ended November 30, 2011 was $2,505,000, compared to $2,787,000 obtained during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $1,005,000 for the nine-month period ended November 30, 2011, compared to a net income of $1,996,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 10% to $13,770,000 for the nine-month period ended November 30, 2011, up from $12,566,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the nine-month period ended November 30, 2011 amounted to a negative $1,818,000, compared to $1,345,000 obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $4,459,000 for the nine-month period ended November 30, 2011, compared to a net income of $519,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements» within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights

Neptune Reports Third Quarter Results>>>>>>NEPT
2012-01-17 08:00 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial results for the three-month and nine-month periods ended November 30, 2011.

Three-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 20% to $5,120,000, for the three-month period ended November 30, 2011, up from $4,272,000 achieved during the corresponding period ended November 30, 2010.
Nutraceutical EBITDA increased to $1,081,000, for the three-month period ended November 30, 2011, up from $425,000 achieved during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $869,000 for the three-month period ended November 30, 2011, compared to a net loss of $13,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 19% to $5,124,000 for the three-month period ended November 30, 2011, up from $4,290,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the three-month period ended November 30, 2011 amounted to ($743,000), compared to ($156,000) obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $1,433,000 for the three-month period ended November 30, 2011, compared to a net loss of $498,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding performance from the neutraceutical business of Neptune," said Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to our leadership positions in North America and Europe, where we have grown both sales and market share this year. We look forward to this afternoon conference call, as we will give a full corporate update to our shareholders," he added.

"We continue to build momentum as demonstrated by our solid third quarter results. During the third quarter our long-term strategic investments in the company's intellectual property protection and valorization helped drive strong revenue performance," said Frederic Harland, Director of finance. "As we look back at the past quarters, we expect continued sales growth driven by price and quantities and are confident in our growth strategy and commercial plans," he added.

Nine-month Ended November 30, 2011 Financial Results

Nutraceutical Business Results

Nutraceutical revenue increased by 10% to $13,756,000, for the nine-month period ended November 30, 2011, up from $12,504,000 achieved during the corresponding period ended November 30, 2010.
EBITDA from nutraceutical business for the nine-month period ended November 30, 2011 was $2,505,000, compared to $2,787,000 obtained during the corresponding period ended November 30, 2010.
Net income from nutraceutical business reached $1,005,000 for the nine-month period ended November 30, 2011, compared to a net income of $1,996,000, for the corresponding period ended November 30, 2010.
Consolidated Results

Revenue increased by 10% to $13,770,000 for the nine-month period ended November 30, 2011, up from $12,566,000 achieved during the corresponding period ended November 30, 2010.
Consolidated EBITDA for the nine-month period ended November 30, 2011 amounted to a negative $1,818,000, compared to $1,345,000 obtained during the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
Net earnings decreased to a net loss of $4,459,000 for the nine-month period ended November 30, 2011, compared to a net income of $519,000 for the corresponding period ended November 30, 2010, due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements» within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com


Top

Old Site | Home | Products | Help | Contact Us | Your Account | System Status

© 2012 Canjex Publishing Ltd. All rights

Acasti Pharma Reports Third Quarter Results
2012-01-17 08:01 ET - News Release


LAVAL, Quebec, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti") (TSX.V:APO), a Neptune Technologies & Bioressources Inc's ("Neptune") subsidiary, today report its financial results for the three and nine-month periods ended November 30, 2011.

Three-Month period

Research and development expenses for the three-month period ended November 30, 2011 amounted to $1,371,000 compared to $354,000 for the corresponding period ended November 30, 2010.
EBITDA for the three-month period ended November 30, 2011 resulted in a negative $1,677,000, compared to a negative $567,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $2,207,000, or $0.03 per share for the three-month period ended November 30, 2011, compared to $618,000, or $0.02 per share, for the corresponding period ended November 30, 2010.
Nine-Month period

Research and development expenses for the nine-month period ended November 30, 2011 amounted to $2,745,000 compared to $942,000 for the corresponding period ended November 30, 2010.
EBITDA for the nine-month period ended November 30, 2011 resulted in a negative $3,624,000, compared to a negative $1,373,000 obtained during the corresponding period ended November 30, 2010.
Net loss amounted to $4,954,000, or $0.08 per share for the nine-month period ended November 30, 2011, compared to $1,866,000, or $0.14 per share, for the corresponding period ended November 30, 2010.
About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Suchforward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could causethe actual results of the Company to be materially different from historical results or from any future results expressed orimplied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with theSecurities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
Tina Sampalis
President
+1 450.686.4555
t.sampalis@acastipharma.com

Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
www.acastipharma.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com

add SDVI-ARGEF-TGLN-NEPT

soliD SDVI today 100% BUYYYYY CURRENT status in short-mid term and another news to come

setting for Runn((( EMLL)))next pr will be niceee$

Mr shaketoday $$..not bad..NSRS nice riding again this week..

EFGU interesting! sweet potential!!
Sweet link:EFGU>>Tayrona on IMDB http://www.imdb.com/company/co0203530/

potential is Huge..also four Wii(TM)..All four titles now include English, French and Spanish.

Graffiti Entertainment's Reader Rabbit Preschool and Kindergarten for Nintendo Wii(TM) Reaches Gold Status


Graffiti Entertainment, Inc. and Signature Devices, Inc. (PINKSHEETS: SDVI) today is announcing that Reader Rabbit Preschool, Kindergarten, 1stGrade and 2ndGrade has been shipped to GameStop stores in North America.
The Reader Rabbit Series has been captivating children for over 20 years with the finest interactive learning products in both schools and homes, having sold over 6 million copies since 1993 and winning 175 awards and accolades! Reader Rabbit Kindergarten has been designed to interest children and encourage learning of basic kindergarten skills such as mathematics, phonics, reading, and listening in multiple contexts.

"These four products are shipping for retailers' back to school schedule. All four titles now include English, French and Spanish. Now a child can not only learn English reading skills, but can practice a 2nd language with these products

(2.52)NEPT Pursues Its IP Strategy With Continuation Applications2012-01-12 08:00 ET - News Release


LAVAL, Quebec, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) announced that it has several "Continuation" applications pending in the U.S. Patent & Trademark Office related to U.S. Pat. No.8,030,348 (the "'348 patent") and U.S. Pat. No.8,057,825 (the "'825 patent"). The '348 patent covers novel omega-3 phospholipid compositions suitable for human consumption, while the '825 patent is directed to methods of using krill extracts to reduce cholesterol, platelet adhesion and plaque formation.

Under United States patent law, a Continuation is a patent application which follows, and claims priority to, an earlier filed patent application. Neptune filed two Continuations claiming the benefit of the '348 patent, which was filed in 2002 and granted in October 2011, and one Continuation claiming the benefit of the '825 patent, which was filed in 2006 and granted in November 2011.

Henri Harland, President and CEO of Neptune, stated: "These Continuations are part of Neptune's continuous efforts to further strengthen our intellectual property and positioning in the US market, and will allow us to pursue additional patent claims that should preclude our competitors from selling their krill oil products in the US market."

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.




CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com

$95.00 a month its very cheap..HTR-Are the amounts that should be paid for the game HTR are paid(brazil guys) .. Ask mart ... two months ago (no) .. they were not paid

Morning Mr shake$ Today$$ is a great day$$

SDVI update 12th Jan 2012)SALES applyzer.com Reader Rabbit 1st Grade - 492174603 (last
http://www.applyzer.com/main.php


Reader Rabbit Kindergarten - 489344055 (last update 12th Jan 2012)
http://www.applyzer.com/main.php

Reader Rabbit Preschool - 473567305 (last update 12th Jan 2012)

http://www.applyzer.com/main.php

Signature Devices, Inc. Offers New Reader Rabbit Apps for Kids on Apple(R) iTunes(R) With Three Titles Available Today

2012-01-11 13:05 ET - News Release


REDWOOD CITY, CA -- (MARKET WIRE) -- 01/11/12


Signature Devices, Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment, proudly announce the immediate availability in the Apple® iTunes® store of three amazing and fun educational apps for children. Reader Rabbit Preschool, Reader Rabbit Kindergarten, and Reader Rabbit First Grade were all developed in-house. They are fully interactive.

"Our creative team has delivered a suite of children's apps that can have a huge appeal and audience. Based on the long-running and popular Reader Rabbit series, we have packed these apps with creativity and technology to assure the largest possible commercial audience. They are priced at $2.99 each, putting them in the reach of all parents and grandparents," said Mart van der Velde, CEO.

"This is the right product to kick off 2012 with a fresh start for Signature Devices, Inc. A success in the children's app market can put a company like ours in a great position for growth, and with these Reader Rabbit apps, we have delivered the goods to the biggest growing segment of the children's educational marketplace. We see large revenue potential in these titles," he added.

Reader Rabbit from SDVI's Graffiti Entertainment is an educational adventure game based on the characters of the popular series for young children, Reader Rabbit. The games teach basic skills to prepare kids for success at school and provide a foundation for further learning.

The games are presented in a colorful cartoon style with short videos, full voice acting, and sing-along songs designed to engage young children while still teaching basic skills. Players will be able to adjust the difficulty level of all mini-games independently which can add hours of replay value.

Great story lines engage children in the interactive fun. In Reader Rabbit First Grade, children help Reader Rabbit and Sam the Lion explore Cloud Nine and Raingear Island in search of the things that Irvin needs. If they find the three items and bring them back to Irvin, he will turn off his machine and stop the avalanche of raingear.

About Signature Devices, Inc.:

SDVI update 12th Jan 2012)SALES applyzer.com Reader Rabbit 1st Grade - 492174603 (last
www.applyzer.com/main.php


Reader Rabbit Kindergarten - 489344055 (last update 12th Jan 2012)
http://www.applyzer.com/main.php

Reader Rabbit Preschool - 473567305 (last update 12th Jan 2012)

http://www.applyzer.com/main.php

Signature Devices, Inc. Offers New Reader Rabbit Apps for Kids on Apple(R) iTunes(R) With Three Titles Available Today

2012-01-11 13:05 ET - News Release


REDWOOD CITY, CA -- (MARKET WIRE) -- 01/11/12


Signature Devices, Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment, proudly announce the immediate availability in the Apple® iTunes® store of three amazing and fun educational apps for children. Reader Rabbit Preschool, Reader Rabbit Kindergarten, and Reader Rabbit First Grade were all developed in-house. They are fully interactive.

"Our creative team has delivered a suite of children's apps that can have a huge appeal and audience. Based on the long-running and popular Reader Rabbit series, we have packed these apps with creativity and technology to assure the largest possible commercial audience. They are priced at $2.99 each, putting them in the reach of all parents and grandparents," said Mart van der Velde, CEO.

"This is the right product to kick off 2012 with a fresh start for Signature Devices, Inc. A success in the children's app market can put a company like ours in a great position for growth, and with these Reader Rabbit apps, we have delivered the goods to the biggest growing segment of the children's educational marketplace. We see large revenue potential in these titles," he added.

Reader Rabbit from SDVI's Graffiti Entertainment is an educational adventure game based on the characters of the popular series for young children, Reader Rabbit. The games teach basic skills to prepare kids for success at school and provide a foundation for further learning.

The games are presented in a colorful cartoon style with short videos, full voice acting, and sing-along songs designed to engage young children while still teaching basic skills. Players will be able to adjust the difficulty level of all mini-games independently which can add hours of replay value.

Great story lines engage children in the interactive fun. In Reader Rabbit First Grade, children help Reader Rabbit and Sam the Lion explore Cloud Nine and Raingear Island in search of the things that Irvin needs. If they find the three items and bring them back to Irvin, he will turn off his machine and stop the avalanche of raingear.

About Signature Devices, Inc.:

PDOS radar bud,look>>SDVI<<$$$applyzer.com Reader Rabbit 1st Grade - 492174603 (last update 12th Jan 2012)
http://www.applyzer.com/main.php


Reader Rabbit Kindergarten - 489344055 (last update 12th Jan 2012)
http://www.applyzer.com/main.php

Reader Rabbit Preschool - 473567305 (last update 12th Jan 2012)

http://www.applyzer.com/main.php

Signature Devices, Inc. Offers New Reader Rabbit Apps for Kids on Apple(R) iTunes(R) With Three Titles Available Today

2012-01-11 13:05 ET - News Release


REDWOOD CITY, CA -- (MARKET WIRE) -- 01/11/12


Signature Devices, Inc. (PINKSHEETS: SDVI) and its subsidiary, Graffiti Entertainment, proudly announce the immediate availability in the Apple® iTunes® store of three amazing and fun educational apps for children. Reader Rabbit Preschool, Reader Rabbit Kindergarten, and Reader Rabbit First Grade were all developed in-house. They are fully interactive.

"Our creative team has delivered a suite of children's apps that can have a huge appeal and audience. Based on the long-running and popular Reader Rabbit series, we have packed these apps with creativity and technology to assure the largest possible commercial audience. They are priced at $2.99 each, putting them in the reach of all parents and grandparents," said Mart van der Velde, CEO.

"This is the right product to kick off 2012 with a fresh start for Signature Devices, Inc. A success in the children's app market can put a company like ours in a great position for growth, and with these Reader Rabbit apps, we have delivered the goods to the biggest growing segment of the children's educational marketplace. We see large revenue potential in these titles," he added.

Reader Rabbit from SDVI's Graffiti Entertainment is an educational adventure game based on the characters of the popular series for young children, Reader Rabbit. The games teach basic skills to prepare kids for success at school and provide a foundation for further learning.

The games are presented in a colorful cartoon style with short videos, full voice acting, and sing-along songs designed to engage young children while still teaching basic skills. Players will be able to adjust the difficulty level of all mini-games independently which can add hours of replay value.

Great story lines engage children in the interactive fun. In Reader Rabbit First Grade, children help Reader Rabbit and Sam the Lion explore Cloud Nine and Raingear Island in search of the things that Irvin needs. If they find the three items and bring them back to Irvin, he will turn off his machine and stop the avalanche of raingear.

About Signature Devices, Inc.:

Based in Redwood City, Calif., Signature Devices, Inc. (SDVI) creates, develops and manufactures advanced information technology, including computer systems, software and electronics products. One of the Company's premier technologies includes a blend of hardware and software for image generation technology used in video games and simulations. Signature Devices also owns Graffiti Entertainment, Inc. (www.graffitientertainment.com), a publisher of interactive entertainment software for advanced entertainment consoles.

The information in this press release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.